Effect of topiramate on cognition in obese children

Neurology

Volumn 67, Issue 7, 2006, Pages 1307-1308

  Aarsen, Femke K ^a   Van Den Akker, Erica L T ^a   Drop, Stenvert L S ^a   Catsman Berrevoets, Coriene E ^a  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

TOPIRAMATE;

ADOLESCENT; ADULT; ARTICLE; ATTENTION; BINGE EATING DISORDER; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; COGNITION; COGNITIVE DEFECT; DEPTH PERCEPTION; DIZZINESS; DOSE TIME EFFECT RELATION; DROWSINESS; EPILEPSY; FEMALE; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; INTELLIGENCE; LANGUAGE; MALE; MEMORY; MIGRAINE; NEUROLOGIC DISEASE; OBESITY; PRADER WILLI SYNDROME; PRIORITY JOURNAL; WEIGHT REDUCTION;

ADOLESCENT; ANTI-OBESITY AGENTS; CHILD; CHILD, PRESCHOOL; COGNITION; COGNITION DISORDERS; FEMALE; FRUCTOSE; HUMANS; MALE; OBESITY;

EID: 33749820287     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000238099.36998.6b     Document Type: Article

References (7)

1. Silberstein SD, Ben-Menachem E, Shank RP, Wiegand F. Topiramate monotherapy in epilepsy and migraine prevention. Clin Ther 2005;27:154-165.
2. Gilliam FG, Veloso F, Bomhof MAM, et al. A dose-comparison trial of topiramate as monotherapy in recently diagnosed partial epilepsy. Neurology 2003;60:196-202.
3. McElroy SL, Arnold LM, Shapira NA, et al. Topiramate in the treatment of binge eating disorder associated with obesity: a randomized placebo-controlled trial. Am J Psychiatry 2003;160:255-261.
4. Smathers SA, Wilson JG, Nigro MA. Topiramate effectiveness in Prader-Willi syndrome. Pediatr Neurol 2003;28:130-133.
5. Mohamed K, Appleton R, Rosenbloom L. Efficacy and tolerability of topiramate in childhood and adolescent epilepsy: a clinical experience. Seizure 2000;9:137-141.
6. Vila G, Zipper E, Dabras M, et al. Mental disorders in obese children and adolescents. Psychosom Med 2004;66:387-394.
7. Kanner AM, Wuu J, Faught E, et al. A past psychiatric history may be a risk factor for topiramate-related psychiatric and cognitive adverse events. Epilepsy Behav 2003;4:548-552.